Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group SEC filings document financial results, governance actions and material events for a global health company operating through Cigna Healthcare, Evernorth Health Services and related subsidiaries. Form 8-K reports cover results of operations and financial condition, Regulation FD outlook disclosures, board and committee changes, leadership succession matters and shareholder meeting results.
Proxy materials describe director elections, executive compensation, shareholder voting items, board composition and governance practices. The filing record also includes exhibits for earnings releases and Inline XBRL cover data, tying formal disclosures to the company’s pharmacy benefit services, specialty and care services, health benefits operations, compliance oversight and public-company capital structure.
The Cigna Group announced a planned leadership transition and reaffirmed its 2026 financial outlook. Brian C. Evanko, currently president and chief operating officer, will become chief executive officer on July 1, 2026, succeeding David M. Cordani, who will retire as CEO and become executive chair of the board.
The board also elected Evanko as a director effective April 1, 2026, and named Eric J. Foss lead independent director, while revising committee leadership across audit, governance, finance and technology, and people resources. Effective July 1, 2026, Evanko’s compensation will include a $1,300,000 base salary, a $2,600,000 Enterprise Incentive Plan target and a $15,100,000 long‑term incentive target, plus a one‑time $3,500,000 transitional equity award tied to assuming the CEO role. Cordani, as executive chair, will receive a $1,000,000 base salary and a $2,000,000 incentive target.
The company reaffirmed projected full‑year 2026 consolidated adjusted income from operations of at least $30.25 per share, along with Evernorth pre‑tax adjusted income from operations of at least $6.9 billion and Cigna Healthcare pre‑tax adjusted income from operations of at least $4.5 billion, using its non‑GAAP adjusted income from operations metric.
The Cigna Group filed an update affirming its outlook for 2026. Company officials expect full-year 2026 consolidated adjusted income from operations of at least $30.25 per share, and plan to communicate this reaffirmed guidance in upcoming meetings with investors and analysts.
The filing explains that adjusted income from operations is a non-GAAP profit measure that starts from shareholders’ net income and removes net investment gains or losses, amortization of acquired intangibles, special items, and certain joint venture investment results. It emphasizes that this metric is used internally to analyze underlying business performance and trends.
The company notes it cannot reasonably reconcile this forward-looking non-GAAP measure to GAAP shareholders’ net income because future investment results and special items are unpredictable and may vary materially. Extensive cautionary language highlights risks such as healthcare cost trends, regulatory changes, technology and cybersecurity issues, economic conditions, and execution on strategic initiatives, all of which could cause actual results to differ from the outlook.
The Cigna Group filed its annual report describing a large, diversified global health business built around two main segments: Evernorth Health Services and Cigna Healthcare. Evernorth provides pharmacy benefit management, specialty pharmacy, care services and a new transparent, rebate-free pharmacy model that will begin rolling out in 2027–2028. Cigna Healthcare offers medical plans and related benefits in the U.S. and internationally, largely through self-funded employer arrangements.
The company serves more than 185 million customer relationships across over 30 markets with about 67,700 employees, mostly in the U.S. One pharmacy benefit client generated 19% of 2025 external revenue, and U.S. federal agencies contributed 11% of 2024 revenue. The aggregate market value of voting stock held by non‑affiliates was about $88.0 billion as of June 30, 2025, and 263,528,277 common shares were outstanding as of January 30, 2026. The filing also details extensive regulatory exposure, including recent federal legislation affecting pharmacy benefit managers, Affordable Care Act changes, privacy and cybersecurity rules, and the company’s governance framework for artificial intelligence and cybersecurity.
A CI shareholder filed a Form 144 notice to sell 6,109 shares of common stock through Fidelity Brokerage Services LLC on 02/06/2026 on the NYSE, with an aggregate market value of $1,791,895.21.
The filing shows these shares were acquired from the issuer as compensation: 539 shares from restricted stock vesting dated 04/24/2024, and 5,570 shares from a compensation grant dated 01/02/2026. Shares outstanding were 267,125,816 at the time referenced, providing scale for the planned sale.
The Cigna Group filed a current report to note that it issued a press release on February 5, 2026, covering its results for the three months and year ended December 31, 2025. The press release is attached as Exhibit 99.1 and is treated as furnished, not filed, under securities laws.
The Cigna Group director reports a routine deferred compensation transaction. On 11/28/2025, the director converted part of a cash retainer into 108.1939 phantom stock units under Cigna’s Deferred Compensation Plan of 2005 for Directors. Each phantom stock unit is the economic equivalent of one share of The Cigna Group’s common stock and will be settled in cash rather than stock.
After this transaction, the director beneficially owns 1,690.8366 phantom stock units, which includes 8.0936 units acquired through the plan’s dividend reinvestment feature. This filing reflects compensation deferral choices rather than an open‑market trade in Cigna common shares.
The Cigna Group reported that its Board of Directors approved changes to the Board’s committee structure on October 22, 2025, with an effective date of January 1, 2026. The Board undertook a comprehensive review to ensure committee responsibilities align with the company’s strategic priorities, remain balanced, and allow the full Board to spend more time on significant matters.
The changes include adjustments to the responsibilities of the Compliance Committee and updates to the oversight of technology at the Board level. The People Resources Committee’s responsibilities remain without material changes. Detailed descriptions of each committee’s responsibilities are available in their charters on the company’s website.
FMR LLC and Abigail P. Johnson filed an amended Schedule 13G reporting beneficial ownership in The Cigna Group (CI) as of September 30, 2025. They disclose 10,665,555.96 shares of common stock, representing 4.0% of the class.
FMR reports sole voting power over 7,258,548.81 shares and sole dispositive power over 10,665,555.96 shares, with no shared voting or dispositive power. Johnson reports sole dispositive power over 10,665,555.96 shares. The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control.